Fleur V Y Tjong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2206863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term performance of a novel communicating antitachycardia pacing–enabled leadless pacemakerÅand subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study. Heart Rhythm, 2022, , .	0.7	15
2	Common Genetic Variants Contribute to Risk of Transposition of the Great Arteries. Circulation Research, 2022, 130, 166-180.	4.5	15
3	How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace, 2022, 24, 979-1005.	1.7	107
4	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. Heart Rhythm, 2021, 18, 79-87.	0.7	26
5	Patient-reported outcomes in symptom-driven remote arrhythmia monitoring: evaluation of the Dutch HartWacht-telemonitoring programme. European Heart Journal Digital Health, 2021, 2, 224-230.	1.7	1
6	Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy. Journal of Clinical Investigation, 2021, 131, .	8.2	16
7	Rare variants in KDR, encoding VEGF Receptor 2, are associated with tetralogy of Fallot. Genetics in Medicine, 2021, 23, 1952-1960.	2.4	7
8	Tissues attached to retrieved leadless pacemakers: Histopathological evaluation of tissue composition in relation to implantation time and complications. Heart Rhythm, 2021, 18, 2101-2109.	0.7	11
9	Sequential Defects in Cardiac Lineage Commitment and Maturation Cause Hypoplastic Left Heart Syndrome. Circulation, 2021, 144, 1409-1428.	1.6	29
10	Rationale and design of the SafeHeart study: Development and testing of a mHealth tool for the prediction of arrhythmic events and implantable cardioverter-defibrillator therapy. Cardiovascular Digital Health Journal, 2021, 2, S11-S20.	1.3	3
11	Accelerometer-assessed physical behaviour and the association with clinical outcomes in implantable cardioverter defibrillator recipients: A systematic review. Cardiovascular Digital Health Journal, 2021, 3, 46-55.	1.3	2
12	Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand. Heart Rhythm, 2020, 17, 2145-2153.	0.7	23
13	Percutaneous leadless pacemaker implantation in a patient with bilateral venous thoracic outlet syndrome. Journal of Vascular Access, 2019, 20, 105-106.	0.9	4
14	Leadless pacemaker implantation after explantation of infected conventional pacemaker systems: A viable solution?. Heart Rhythm, 2019, 16, 66-71.	0.7	68
15	<i>GATA6</i> mutations: Characterization of two novel patients and a comprehensive overview of the GATA6 genotypic and phenotypic spectrum. American Journal of Medical Genetics, Part A, 2019, 179, 1836-1845.	1.2	16
16	Leadless cardiac pacing systems: current status and future prospects. Expert Review of Medical Devices, 2019, 16, 923-930.	2.8	15
17	Impact of Leadless Pacemaker Therapy on Cardiac and Atrioventricular Valve Function Through 12 Months of Follow-Up. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007124.	4.8	70
18	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. Europace, 2018, 20, 1866-1871.	1.7	16

FLEUR VY TJONG

#	Article	IF	CITATIONS
19	Successful replacement of the longest worldwide in situ Nanostim leadless cardiacÂpacemaker for a Micra Transcatheter Pacing System. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 161-162.	1.3	12
20	Midterm Safety and Performance of a Leadless Cardiac Pacemaker. Circulation, 2018, 137, 633-635.	1.6	18
21	Leadless pacemaker versus transvenous single-chamber pacemaker therapy: A propensity score-matched analysis. Heart Rhythm, 2018, 15, 1387-1393.	0.7	35
22	Healthâ€related quality of life impact of a transcatheter pacing system. Journal of Cardiovascular Electrophysiology, 2018, 29, 1697-1704.	1.7	20
23	The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD. Herzschrittmachertherapie Und Elektrophysiologie, 2018, 29, 355-361.	0.8	34
24	The learning curve associated with the implantation of the Nanostim leadless pacemaker. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 239-247.	1.3	10
25	ClinicalÂparameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 990-995.	1.2	5
26	Permanent Leadless Cardiac Pacemaker Therapy. Circulation, 2017, 135, 1458-1470.	1.6	174
27	Acute and 3-Month Performance ofÂaÂCommunicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. JACC: Clinical Electrophysiology, 2017, 3, 1487-1498.	3.2	57
28	End-of-life Management of Leadless Cardiac Pacemaker Therapy. Arrhythmia and Electrophysiology Review, 2017, 6, 129.	2.4	28
29	Communicating Antitachycardia Pacing-Enabled Leadless Pacemaker and Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2016, 67, 1865-1866.	2.8	53
30	A leadless solution. Europace, 2015, 17, 800-800.	1.7	4
31	Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. Heart Rhythm, 2015, 12, 360-366.	0.7	19
32	Chronic Performance of a LeadlessÂCardiac Pacemaker. Journal of the American College of Cardiology, 2015, 65, 1497-1504.	2.8	104
33	Postmortem Histopathological Examination of a Leadless Pacemaker Shows Partial Encapsulation After 19 Months. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1293-1295.	4.8	27
34	State of the art of leadless pacing. Europace, 2015, 17, 1508-1513.	1.7	73
35	Permanent Leadless Cardiac Pacing. Circulation, 2014, 129, 1466-1471.	1.6	257
36	Mild-to-moderate kidney dysfunction and the risk of sudden cardiac death in the setting of acute myocardial infarction. Heart Rhythm, 2012, 9, 540-545.	0.7	15

#	Article	IF	CITATIONS
37	Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. Journal of Cardiovascular Medicine, 2010, 11, 827-831.	1.5	7